Replimune goes pivotal in uveal melanoma
The group eyes a broader use than Immunocore’s Kimmtrak.
The group eyes a broader use than Immunocore’s Kimmtrak.
The company’s vuso-vec looks similar to Amtagvi, and could have safety and convenience advantages.